Chemotherapeutic suppression of immune enhancement: a primary determinant of successful cancer therapy.
D000818:Animals; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D002470:Cell Survival; D002648:Child; D003520:Cyclophosphamide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D004195:Disease Models, Animal; D006084:Graft Rejection; D006087:Graft vs Host Reaction; D006801:Humans; D007109:Immunity; D007111:Immunity, Cellular; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007700:Kinetics; D008198:Lymph Nodes / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D013154:Spleen / Q000187:drug effects; D013601:T-Lymphocytes; D014181:Transplantation Immunology
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003561:Cytarabine; D003520:Cyclophosphamide